|
GSK Submits European, US Filings for Asthma Med
Drug Discovery & Development GlaxoSmithKline announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for approval as a maintenance treatment for patients with severe eosinophilic asthma, identified by a blood eosinophil count of at least 150 cells … GSK Files for Approval of Mepolizumab in US, Europe for Eosinophilic Asthma GSK submits asthma biologic in US, EU GlaxoSmithKline heads to the FDA with its next big respiratory bet |
View full post on asthma – Google News